Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Melt Pharmaceuticals Names Experienced Executive Brad Osborne As CFO
Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the addition of Brad Osborne as Chief Financial Officer. Osborne brings
Harrow Health Acquires Rights to 4 Branded Eye Drops
IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin
EyePoint Pharma Reports Expanded US Commercial Alliance For DEXYCU With Harrow Health
ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU® and absorb the majority of EyePoint’s DEXYCU commercial organization; EyePoint to retain DEXYCU NDA, revenue
Harrow Health Q3 EPS $(0.31) Down From $0.32 YoY, Sales $18.70M Beat $17.45M Estimate
Harrow Health (NASDAQ:HROW) reported quarterly losses of $(0.31) per share. This is a 196.88 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Looking Into Harrow Health’s Return On Capital Employed
According to Benzinga Pro, during Q2, Harrow Health (NASDAQ:HROW) earned $4.17 million, a 72.13% increase from the preceding quarter. Harrow Health also posted a total of $18.13 million in sales, a 17.43% increase since Q1.
Harrow Health Reports Provides $13.5M Senior Secured Loan To Melt Pharma
Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic-focused healthcare company, and Melt